Copyright Reports & Markets. All rights reserved.

Global Breakthrough Therapy (BT) Designation Market Size, Status and Forecast 2021-2027

Request for Sample of this report
Buy now

1 Report Overview

  • 1.1 Study Scope
  • 1.2 Market Analysis by Type
    • 1.2.1 Global Breakthrough Therapy (BT) Designation Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
    • 1.2.2 Oncology
    • 1.2.3 Infectious Diseases
    • 1.2.4 Rare Diseases
    • 1.2.5 Autoimmune Diseases
    • 1.2.6 Pulmonary Diseases
    • 1.2.7 Neurological Disorders
    • 1.2.8 Others
  • 1.3 Market by Application
    • 1.3.1 Global Breakthrough Therapy (BT) Designation Market Share by Application: 2016 VS 2021 VS 2027
    • 1.3.2 Hospital
    • 1.3.3 Clinic
    • 1.3.4 Research Institute
    • 1.3.5 Laboratories
    • 1.3.6 Others
  • 1.4 Study Objectives
  • 1.5 Years Considered

2 Global Growth Trends

  • 2.1 Global Breakthrough Therapy (BT) Designation Market Perspective (2016-2027)
  • 2.2 Breakthrough Therapy (BT) Designation Growth Trends by Regions
    • 2.2.1 Breakthrough Therapy (BT) Designation Market Size by Regions: 2016 VS 2021 VS 2027
    • 2.2.2 Breakthrough Therapy (BT) Designation Historic Market Share by Regions (2016-2021)
    • 2.2.3 Breakthrough Therapy (BT) Designation Forecasted Market Size by Regions (2022-2027)
  • 2.3 Breakthrough Therapy (BT) Designation Industry Dynamic
    • 2.3.1 Breakthrough Therapy (BT) Designation Market Trends
    • 2.3.2 Breakthrough Therapy (BT) Designation Market Drivers
    • 2.3.3 Breakthrough Therapy (BT) Designation Market Challenges
    • 2.3.4 Breakthrough Therapy (BT) Designation Market Restraints

3 Competition Landscape by Key Players

  • 3.1 Global Top Breakthrough Therapy (BT) Designation Players by Revenue
    • 3.1.1 Global Top Breakthrough Therapy (BT) Designation Players by Revenue (2016-2021)
    • 3.1.2 Global Breakthrough Therapy (BT) Designation Revenue Market Share by Players (2016-2021)
  • 3.2 Global Breakthrough Therapy (BT) Designation Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
  • 3.3 Players Covered: Ranking by Breakthrough Therapy (BT) Designation Revenue
  • 3.4 Global Breakthrough Therapy (BT) Designation Market Concentration Ratio
    • 3.4.1 Global Breakthrough Therapy (BT) Designation Market Concentration Ratio (CR5 and HHI)
    • 3.4.2 Global Top 10 and Top 5 Companies by Breakthrough Therapy (BT) Designation Revenue in 2020
  • 3.5 Breakthrough Therapy (BT) Designation Key Players Head office and Area Served
  • 3.6 Key Players Breakthrough Therapy (BT) Designation Product Solution and Service
  • 3.7 Date of Enter into Breakthrough Therapy (BT) Designation Market
  • 3.8 Mergers & Acquisitions, Expansion Plans

4 Breakthrough Therapy (BT) Designation Breakdown Data by Type

  • 4.1 Global Breakthrough Therapy (BT) Designation Historic Market Size by Type (2016-2021)
  • 4.2 Global Breakthrough Therapy (BT) Designation Forecasted Market Size by Type (2022-2027)

5 Breakthrough Therapy (BT) Designation Breakdown Data by Application

  • 5.1 Global Breakthrough Therapy (BT) Designation Historic Market Size by Application (2016-2021)
  • 5.2 Global Breakthrough Therapy (BT) Designation Forecasted Market Size by Application (2022-2027)

6 North America

  • 6.1 North America Breakthrough Therapy (BT) Designation Market Size (2016-2027)
  • 6.2 North America Breakthrough Therapy (BT) Designation Market Size by Type
    • 6.2.1 North America Breakthrough Therapy (BT) Designation Market Size by Type (2016-2021)
    • 6.2.2 North America Breakthrough Therapy (BT) Designation Market Size by Type (2022-2027)
    • 6.2.3 North America Breakthrough Therapy (BT) Designation Market Size by Type (2016-2027)
  • 6.3 North America Breakthrough Therapy (BT) Designation Market Size by Application
    • 6.3.1 North America Breakthrough Therapy (BT) Designation Market Size by Application (2016-2021)
    • 6.3.2 North America Breakthrough Therapy (BT) Designation Market Size by Application (2022-2027)
    • 6.3.3 North America Breakthrough Therapy (BT) Designation Market Size by Application (2016-2027)
  • 6.4 North America Breakthrough Therapy (BT) Designation Market Size by Country
    • 6.4.1 North America Breakthrough Therapy (BT) Designation Market Size by Country (2016-2021)
    • 6.4.2 North America Breakthrough Therapy (BT) Designation Market Size by Country (2022-2027)
    • 6.4.3 United States
    • 6.4.3 Canada

7 Europe

  • 7.1 Europe Breakthrough Therapy (BT) Designation Market Size (2016-2027)
  • 7.2 Europe Breakthrough Therapy (BT) Designation Market Size by Type
    • 7.2.1 Europe Breakthrough Therapy (BT) Designation Market Size by Type (2016-2021)
    • 7.2.2 Europe Breakthrough Therapy (BT) Designation Market Size by Type (2022-2027)
    • 7.2.3 Europe Breakthrough Therapy (BT) Designation Market Size by Type (2016-2027)
  • 7.3 Europe Breakthrough Therapy (BT) Designation Market Size by Application
    • 7.3.1 Europe Breakthrough Therapy (BT) Designation Market Size by Application (2016-2021)
    • 7.3.2 Europe Breakthrough Therapy (BT) Designation Market Size by Application (2022-2027)
    • 7.3.3 Europe Breakthrough Therapy (BT) Designation Market Size by Application (2016-2027)
  • 7.4 Europe Breakthrough Therapy (BT) Designation Market Size by Country
    • 7.4.1 Europe Breakthrough Therapy (BT) Designation Market Size by Country (2016-2021)
    • 7.4.2 Europe Breakthrough Therapy (BT) Designation Market Size by Country (2022-2027)
    • 7.4.3 Germany
    • 7.4.4 France
    • 7.4.5 U.K.
    • 7.4.6 Italy
    • 7.4.7 Russia
    • 7.4.8 Nordic

8 Asia-Pacific

  • 8.1 Asia-Pacific Breakthrough Therapy (BT) Designation Market Size (2016-2027)
  • 8.2 Asia-Pacific Breakthrough Therapy (BT) Designation Market Size by Type
    • 8.2.1 Asia-Pacific Breakthrough Therapy (BT) Designation Market Size by Type (2016-2021)
    • 8.2.2 Asia-Pacific Breakthrough Therapy (BT) Designation Market Size by Type (2022-2027)
    • 8.2.3 Asia-Pacific Breakthrough Therapy (BT) Designation Market Size by Type (2016-2027)
  • 8.3 Asia-Pacific Breakthrough Therapy (BT) Designation Market Size by Application
    • 8.3.1 Asia-Pacific Breakthrough Therapy (BT) Designation Market Size by Application (2016-2021)
    • 8.3.2 Asia-Pacific Breakthrough Therapy (BT) Designation Market Size by Application (2022-2027)
    • 8.3.3 Asia-Pacific Breakthrough Therapy (BT) Designation Market Size by Application (2016-2027)
  • 8.4 Asia-Pacific Breakthrough Therapy (BT) Designation Market Size by Region
    • 8.4.1 Asia-Pacific Breakthrough Therapy (BT) Designation Market Size by Region (2016-2021)
    • 8.4.2 Asia-Pacific Breakthrough Therapy (BT) Designation Market Size by Region (2022-2027)
    • 8.4.3 China
    • 8.4.4 Japan
    • 8.4.5 South Korea
    • 8.4.6 Southeast Asia
    • 8.4.7 India
    • 8.4.8 Australia

9 Latin America

  • 9.1 Latin America Breakthrough Therapy (BT) Designation Market Size (2016-2027)
  • 9.2 Latin America Breakthrough Therapy (BT) Designation Market Size by Type
    • 9.2.1 Latin America Breakthrough Therapy (BT) Designation Market Size by Type (2016-2021)
    • 9.2.2 Latin America Breakthrough Therapy (BT) Designation Market Size by Type (2022-2027)
    • 9.2.3 Latin America Breakthrough Therapy (BT) Designation Market Size by Type (2016-2027)
  • 9.3 Latin America Breakthrough Therapy (BT) Designation Market Size by Application
    • 9.3.1 Latin America Breakthrough Therapy (BT) Designation Market Size by Application (2016-2021)
    • 9.3.2 Latin America Breakthrough Therapy (BT) Designation Market Size by Application (2022-2027)
    • 9.3.3 Latin America Breakthrough Therapy (BT) Designation Market Size by Application (2016-2027)
  • 9.4 Latin America Breakthrough Therapy (BT) Designation Market Size by Country
    • 9.4.1 Latin America Breakthrough Therapy (BT) Designation Market Size by Country (2016-2021)
    • 9.4.2 Latin America Breakthrough Therapy (BT) Designation Market Size by Country (2022-2027)
    • 9.4.3 Mexico
    • 9.4.4 Brazil

10 Middle East & Africa

  • 10.1 Middle East & Africa Breakthrough Therapy (BT) Designation Market Size (2016-2027)
  • 10.2 Middle East & Africa Breakthrough Therapy (BT) Designation Market Size by Type
    • 10.2.1 Middle East & Africa Breakthrough Therapy (BT) Designation Market Size by Type (2016-2021)
    • 10.2.2 Middle East & Africa Breakthrough Therapy (BT) Designation Market Size by Type (2022-2027)
    • 10.2.3 Middle East & Africa Breakthrough Therapy (BT) Designation Market Size by Type (2016-2027)
  • 10.3 Middle East & Africa Breakthrough Therapy (BT) Designation Market Size by Application
    • 10.3.1 Middle East & Africa Breakthrough Therapy (BT) Designation Market Size by Application (2016-2021)
    • 10.3.2 Middle East & Africa Breakthrough Therapy (BT) Designation Market Size by Application (2022-2027)
    • 10.3.3 Middle East & Africa Breakthrough Therapy (BT) Designation Market Size by Application (2016-2027)
  • 10.4 Middle East & Africa Breakthrough Therapy (BT) Designation Market Size by Country
    • 10.4.1 Middle East & Africa Breakthrough Therapy (BT) Designation Market Size by Country (2016-2021)
    • 10.4.2 Middle East & Africa Breakthrough Therapy (BT) Designation Market Size by Country (2022-2027)
    • 10.4.3 Turkey
    • 10.4.4 Saudi Arabia
    • 10.4.5 UAE

11 Key Players Profiles

  • 11.1 Roche
    • 11.1.1 Roche Company Details
    • 11.1.2 Roche Business Overview
    • 11.1.3 Roche Breakthrough Therapy (BT) Designation Introduction
    • 11.1.4 Roche Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021)
    • 11.1.5 Roche Recent Development
  • 11.2 Abbvie
    • 11.2.1 Abbvie Company Details
    • 11.2.2 Abbvie Business Overview
    • 11.2.3 Abbvie Breakthrough Therapy (BT) Designation Introduction
    • 11.2.4 Abbvie Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021)
    • 11.2.5 Abbvie Recent Development
  • 11.3 Novartis International AG
    • 11.3.1 Novartis International AG Company Details
    • 11.3.2 Novartis International AG Business Overview
    • 11.3.3 Novartis International AG Breakthrough Therapy (BT) Designation Introduction
    • 11.3.4 Novartis International AG Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021)
    • 11.3.5 Novartis International AG Recent Development
  • 11.4 Janssen
    • 11.4.1 Janssen Company Details
    • 11.4.2 Janssen Business Overview
    • 11.4.3 Janssen Breakthrough Therapy (BT) Designation Introduction
    • 11.4.4 Janssen Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021)
    • 11.4.5 Janssen Recent Development
  • 11.5 BMS
    • 11.5.1 BMS Company Details
    • 11.5.2 BMS Business Overview
    • 11.5.3 BMS Breakthrough Therapy (BT) Designation Introduction
    • 11.5.4 BMS Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021)
    • 11.5.5 BMS Recent Development
  • 11.6 Eli Lilly
    • 11.6.1 Eli Lilly Company Details
    • 11.6.2 Eli Lilly Business Overview
    • 11.6.3 Eli Lilly Breakthrough Therapy (BT) Designation Introduction
    • 11.6.4 Eli Lilly Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021)
    • 11.6.5 Eli Lilly Recent Development
  • 11.7 Gilead
    • 11.7.1 Gilead Company Details
    • 11.7.2 Gilead Business Overview
    • 11.7.3 Gilead Breakthrough Therapy (BT) Designation Introduction
    • 11.7.4 Gilead Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021)
    • 11.7.5 Gilead Recent Development
  • 11.8 Sanofi
    • 11.8.1 Sanofi Company Details
    • 11.8.2 Sanofi Business Overview
    • 11.8.3 Sanofi Breakthrough Therapy (BT) Designation Introduction
    • 11.8.4 Sanofi Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021)
    • 11.8.5 Sanofi Recent Development
  • 11.9 Regeneron
    • 11.9.1 Regeneron Company Details
    • 11.9.2 Regeneron Business Overview
    • 11.9.3 Regeneron Breakthrough Therapy (BT) Designation Introduction
    • 11.9.4 Regeneron Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021)
    • 11.9.5 Regeneron Recent Development
  • 11.10 Acadia
    • 11.10.1 Acadia Company Details
    • 11.10.2 Acadia Business Overview
    • 11.10.3 Acadia Breakthrough Therapy (BT) Designation Introduction
    • 11.10.4 Acadia Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021)
    • 11.10.5 Acadia Recent Development
  • 11.11 Boehringer Ingelheim
    • 11.11.1 Boehringer Ingelheim Company Details
    • 11.11.2 Boehringer Ingelheim Business Overview
    • 11.11.3 Boehringer Ingelheim Breakthrough Therapy (BT) Designation Introduction
    • 11.11.4 Boehringer Ingelheim Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021)
    • 11.11.5 Boehringer Ingelheim Recent Development
  • 11.12 Amgen
    • 11.12.1 Amgen Company Details
    • 11.12.2 Amgen Business Overview
    • 11.12.3 Amgen Breakthrough Therapy (BT) Designation Introduction
    • 11.12.4 Amgen Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021)
    • 11.12.5 Amgen Recent Development
  • 11.13 AstraZeneca
    • 11.13.1 AstraZeneca Company Details
    • 11.13.2 AstraZeneca Business Overview
    • 11.13.3 AstraZeneca Breakthrough Therapy (BT) Designation Introduction
    • 11.13.4 AstraZeneca Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021)
    • 11.13.5 AstraZeneca Recent Development
  • 11.14 GlaxoSmithKline
    • 11.14.1 GlaxoSmithKline Company Details
    • 11.14.2 GlaxoSmithKline Business Overview
    • 11.14.3 GlaxoSmithKline Breakthrough Therapy (BT) Designation Introduction
    • 11.14.4 GlaxoSmithKline Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021)
    • 11.14.5 GlaxoSmithKline Recent Development
  • 11.15 Vertex
    • 11.15.1 Vertex Company Details
    • 11.15.2 Vertex Business Overview
    • 11.15.3 Vertex Breakthrough Therapy (BT) Designation Introduction
    • 11.15.4 Vertex Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021)
    • 11.15.5 Vertex Recent Development
  • 11.16 Alexion
    • 11.16.1 Alexion Company Details
    • 11.16.2 Alexion Business Overview
    • 11.16.3 Alexion Breakthrough Therapy (BT) Designation Introduction
    • 11.16.4 Alexion Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021)
    • 11.16.5 Alexion Recent Development
  • 11.17 Merck
    • 11.17.1 Merck Company Details
    • 11.17.2 Merck Business Overview
    • 11.17.3 Merck Breakthrough Therapy (BT) Designation Introduction
    • 11.17.4 Merck Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021)
    • 11.17.5 Merck Recent Development
  • 11.18 Jazz Pharmaceuticals
    • 11.18.1 Jazz Pharmaceuticals Company Details
    • 11.18.2 Jazz Pharmaceuticals Business Overview
    • 11.18.3 Jazz Pharmaceuticals Breakthrough Therapy (BT) Designation Introduction
    • 11.18.4 Jazz Pharmaceuticals Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021)
    • 11.18.5 Jazz Pharmaceuticals Recent Development
  • 11.18 Exelixis

.1 Exelixis Company Details

    .2 Exelixis Business Overview

      .3 Exelixis Breakthrough Therapy (BT) Designation Introduction

        .4 Exelixis Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021)

          .5 Exelixis Recent Development

          • 11.20 Eisai
            • 11.20.1 Eisai Company Details
            • 11.20.2 Eisai Business Overview
            • 11.20.3 Eisai Breakthrough Therapy (BT) Designation Introduction
            • 11.20.4 Eisai Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021)
            • 11.20.5 Eisai Recent Development
          • 11.21 Takeda
            • 11.21.1 Takeda Company Details
            • 11.21.2 Takeda Business Overview
            • 11.21.3 Takeda Breakthrough Therapy (BT) Designation Introduction
            • 11.21.4 Takeda Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021)
            • 11.21.5 Takeda Recent Development
          • 11.22 Pfizer
            • 11.22.1 Pfizer Company Details
            • 11.22.2 Pfizer Business Overview
            • 11.22.3 Pfizer Breakthrough Therapy (BT) Designation Introduction
            • 11.22.4 Pfizer Revenue in Breakthrough Therapy (BT) Designation Business (2016-2021)
            • 11.22.5 Pfizer Recent Development

          12 Analyst's Viewpoints/Conclusions

            13 Appendix

            • 13.1 Research Methodology
              • 13.1.1 Methodology/Research Approach
              • 13.1.2 Data Source
            • 13.2 Disclaimer

            Breakthrough Therapy (BT) Designation market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Breakthrough Therapy (BT) Designation market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

            Segment by Type
            Oncology
            Infectious Diseases
            Rare Diseases
            Autoimmune Diseases
            Pulmonary Diseases
            Neurological Disorders
            Others

            Segment by Application
            Hospital
            Clinic
            Research Institute
            Laboratories
            Others

            By Region
            North America
            U.S.
            Canada
            Europe
            Germany
            France
            U.K.
            Italy
            Russia
            Nordic
            Rest of Europe
            Asia-Pacific
            China
            Japan
            South Korea
            Southeast Asia
            India
            Australia
            Rest of Asia
            Latin America
            Mexico
            Brazil
            Rest of Latin America
            Middle East & Africa
            Turkey
            Saudi Arabia
            UAE
            Rest of MEA

            By Company
            Roche
            Abbvie
            Novartis International AG
            Janssen
            BMS
            Eli Lilly
            Gilead
            Sanofi
            Regeneron
            Janssen
            BMS
            Amgen
            AstraZeneca
            GlaxoSmithKline
            Vertex
            Alexion
            Merck
            Jazz Pharmaceuticals
            Exelixis
            Eisai
            Takeda

            Buy now